Company Description
Biodesix, Inc. operates as a diagnostic solutions company.
The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions.
In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies.
The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006.
Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
| Country | United States |
| Founded | 2005 |
| IPO Date | Oct 28, 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 273 |
| CEO | Scott Hutton |
Contact Details
Address: 919 West Dillon Road Louisville, Colorado 80027 United States | |
| Phone | 303 417 0500 |
| Website | biodesix.com |
Stock Details
| Ticker Symbol | BDSX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001439725 |
| CUSIP Number | 09075X108 |
| ISIN Number | US09075X1081 |
| Employer ID | 20-3986492 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Scott Hutton | President, Chief Executive Officer and Director |
| Robin Harper Cowie | Chief Financial Officer, Secretary and Treasurer |
| Kieran O'Kane | Chief Commercial Officer |
| Dr. Heinrich Röder | Founder and Chief Technology Officer |
| Jessica Olbricht | Senior Director of Human Resources |
| Dr. Gary Anthony Pestano Ph.D. | Chief Development Officer |
| Bobbi Coffin | Chief Growth Officer |
| Dr. James R. Jett M.D. | Co-Chief Medical Officer |
| Dr. Steven C. Springmeyer | Co-Chief Medical Officer |
| Christopher Vazquez | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 21, 2025 | 8-K | Current Report |
| May 20, 2025 | SCHEDULE 13D/A | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2025 | 8-K | Current Report |